Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

SAGE Trial for Refractory Status Epilepticus

  • Broadcast in Health
  • 0 comments
Epilepsy Talk Radio

Epilepsy Talk Radio

×  

Follow This Show

If you liked this show, you should follow Epilepsy Talk Radio.

Call in to speak with the host

(347) 215-9676

h:22504
s:6505485
archived

In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Steve Kanes, MD, PhD, Chief Medical Officer at SAGE Therapeutics about the SAGE 547 Trial in Status Epilepticus.

SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE). SAGE-547 demonstrated robust findings in preclinical models of SE, including significantly increased efficacy over current standard-of-care benzodiazepine treatment, and compelling early human experience data.

After the interview, you can learn more about refractory epilepsy at: http://www.epilepsy.com/learn/refractory-epilepsy.

Comments

 comments